Zhijing Liu - China Biologic Insider

China Biologic Products Holdings Inc -- USA Stock  

USD 81.68  1.38  1.66%

Corporate VP

Ms. Zhijing Liu is Corporationrationrate Vice President of China Biologic Products, Inc. She oversees plasma quality management, plasma resource development and matters related to regulatory affairs. From January 2010 to May 2011, Ms. Liu held various management positions at our Company, including being the Chief Representative of the Companys Beijing office. From May 2011 to August 2012, Ms. Liu was our Director of the Regulatory Affairs and Administration
Age: 62  VP Since 2012      
86 10 6598 3111  http://www.chinabiologic.com
Liu has more than 30 years of experience in China?s pharmaceutical industry, holding various senior marketing, human resource, consulting and general management positions with various pharmaceutical organizations. Prior to joining us, Ms. Liu was general manager of Zhongbang Medical Technology Company, an affiliate of Hospital Management Institute of Ministry of Health.

Management Efficiency

The company has return on total asset (ROA) of 12.01 % which means that it generated profit of $12.01 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 13.87 % meaning that it created $13.87 on every $100 dollars invested by stockholders.

Entity Summary

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the Peoples Republic of China. China Biologic Products Holdings, Inc. is headquartered in Beijing, the Peoples Republic of China. China Biologic operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1871 people.China Biologic Products Holdings Inc (CBPO) is traded on NASDAQ in USA. It is located in CHINA and employs 1,871 people. China Biologic is listed under Pharmaceutical Products category by Fama And French industry classification.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add China Biologic Products Holdings Inc to your portfolio

Top Management

China Biologic Products Leadership Team
Min Fang, Director, MBA
Zhijing Liu, VP
Ming Yang, CFO, CPA
Joseph Chow, Director, MBA
Gang Yang, VP
Xiaosheng Shao, Director
Ming Yin, VP, MBA
Zhijun Tong, Director
Yungang Lu, Director
Wenfang Liu, Director, Ph.D
Wai Yeung, Director
David Li, Director, MBA
David Gao, Chairman, MBA
Xiaoying Gao, Chairman, MBA

Stock Performance

China Biologic Performance Indicators